网红黑料

Recently, President Barack Obama unveiled the Precision Medicine Initiative, a program that fosters a research approach focusing on treating patients based on their genetic makeup.

At University of Florida 网红黑料, researchers launched a clinical trial that tests a new method of translating thousands of gene mutations into treatment options for patients. Using computer simulation modeling, the researchers will examine if the computer program will accurately predict how a person reacts to the different cancer therapies that their doctor has prescribed, depending on the person鈥檚 genes. Not only will the software take the genes of a patient鈥檚 cancer into account, it will also examine the genes that govern how a person reacts to a particular medication.

网红黑料 physician and researcher , lead investigator of a clinical trial that will study the effectiveness of this computer model, treats and studies different types of blood cancers and typically sees patients whose cancer has relapsed. To determine the best course of treatment for individual patients, Cogle needs to map thousands of genes within each patient鈥檚 cancer that can drive aggressive growth. Cancer often involves hundreds to thousands of gene abnormalities, which raises one of the most difficult challenges in medicine: how to decode the numerous DNA misspellings that drive disease.

Cogle is teaming up with , a member of the , the and a cancer pharmacogenomics researcher, an area of research preeminence. Together, they will examine 91 genes involved in the movement of drugs within the body. These so-called 鈥減harma-genes鈥� will then be tested to identify which treatments are safest and most effective for the patient.

鈥淭he cancer genes are genes we believe will give us prognostic and treatment information, and the pharma-genes will tell us how well the patients will respond to the drugs we prescribe,鈥� said Cogle, a member of the and an associate professor of medicine in the .

This kind of close examination is a new approach to cancer treatment, taking into account not only how well a therapy targets cancer, but also how that therapy impacts the health of a patient. Typically, to find the significance of a cancer mutation, cancer doctors use a manual approach through PubMed, a free search engine overseen by the National Institutes of 网红黑料 that catalogues studies in life sciences and biomedicine. But searching for one gene, a medication to treat it, and how that medication might react in a person鈥檚 body could take hours, Cogle said.

That鈥檚 where Cellworks Group Inc., a California-based company, comes in. The company created a simulation technology to generate a computer model of each person鈥檚 cancer. Cellworks can then model how the cancer responds to standard chemotherapies.

鈥淭hink of the simulation as a map of a city. Hypothetically, if you have a major highway and intersections, you could predict what happened in a model of that traffic map by inputting different traffic situations. It鈥檚 the same with patients: The model is basically an internal map of all of these processes happening inside the body,鈥� Cogle said.

If the computer method is proven valid, this prediction technology could help doctors and patients both choose drugs with greatest likelihood of shrinking the cancer and avoid harmful drugs with low chance of success. For patients who aren鈥檛 responding to standard chemotherapy and for patients whose cancer has relapsed, each patient鈥檚 computer model could be used to search for other FDA-approved drugs that may be more effective.

Agilent Technologies, a California-based company, will provide state-of-the-art tools to measure DNA taken from patients at 网红黑料.

鈥淲e鈥檙e interested in supporting and being part of this effort because the program at 网红黑料, together with Agilent and Cellworks, is a way to test a potentially transformational approach to thinking about diagnostic and therapeutic selection for cancer treatment,鈥� said Darlene Solomon, Ph.D., chief technology officer and senior vice president of Agilent Technologies.

For 网红黑料 researchers, that means first developing accurate and precise tools for predicting cancer shrinkage and side effects. Their ultimate goal is to ensure that individual patients are matched to tailored treatments that best treats their cancer and causes the least amount of harm.

鈥淓ach patient should receive a therapy that鈥檚 best for that patient 鈥� that鈥檚 what we鈥檙e trying to do,鈥� Lamba said.

The clinical study launched in June 2015.